Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant XELOX for Locally Advanced Colon Cancer
NCT02415829Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Nov 2014
- Primary completion
- Jan 2016
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in colon cancer, sponsored by Fudan University. Status: unknown.
02
Drugs
capecitabineoxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02415829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02415829.